Condition: Glioblastoma · Astrocytoma · Venous Thromboembolism · Sponsor: University of Vermont Medical Center
This is an open label study of apixaban for venous thromboembolism prevention in patients with newly diagnosed grade 4 glioma.
This description comes directly from the study's public registry record.
Alissa A Thomas, MD · 802-847-8400 · alissa.thomas@med.uvm.edu
Donna Silver · 802-656-5040 · irb@uvm.edu
Always discuss trial participation with your own doctor first.
| University of Vermont Medical Center | Burlington, Vermont, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05683808